Royalty Pharma plc has released a groundbreaking report conducted by Deloitte, titled "Role of Royalties in Funding Biopharma Innovation," which provides an in-depth analysis of the biopharma royalty market. The study, a first of its kind, gathers insights from over 110 biopharma executives, revealing the strategic importance of royalties in the industry's evolving capital landscape. Key findings highlight the non-dilutive nature of royalties, their flexibility, and positive investor perception, making them an attractive funding option for biopharma companies. The report suggests that royalties are increasingly recognized as vital to supporting innovation and scientific breakthroughs, with 87% of surveyed executives considering them in capital raising plans for the next three years. This marks a shift towards a diversified funding model in biopharma, emphasizing the significant role royalties play in providing flexible, large-scale capital. The full report is available for download on Deloitte's and Royalty Pharma's websites.